Direct Biologics

Direct Biologics is a pioneering leader and cGMP manufacturer of regenerative biologic products, driven by science and innovation. Our company is dedicated to delivering the next generation of medical therapeutics that will revolutionize the treatment of human disease. We have developed a range of naturally bioactive products for regenerative therapies, utilizing novel technologies to create Extracellular Vesicle (EV) products derived from adult human mesenchymal stem/stromal cells. These EVs contain bioactive molecules with significant clinical therapeutic potential.

At Direct Biologics, we pride ourselves on being at the forefront of innovation within the biotechnology sector. Our commitment to quality and patient safety is underpinned by robust cGxP quality systems that are implemented at every stage of our product development process. We harness extensive research efforts to deliver cutting-edge clinical insights, aiming to provide solutions that significantly improve patient outcomes. Through the introduction of our EV products, we have set a new standard for therapeutic biologics that emphasizes unparalleled quality and safety. With an active approach toward regulatory compliance, we continuously strive for excellence in our product offerings and clinical initiatives, ensuring we meet the evolving needs of the medical community and the patients we serve.